Kayothera Inc.
- Biotech or pharma, therapeutic R&D
Redefining the retinoid pathway: Developing 1st-in-class inhibitors of the retinoid and rexinoid nuclear receptor pathways for beta cell regeneration in type 2 diabetes, heart failure/dyslipidemia, obesity and cancer.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}